Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012

JAMA

Volumn 311, Issue 13, 2014, Pages 1308-1316

  Kaukonen, Kirsi Maija ^a,b   Bailey, Michael ^a   Suzuki, Satoshi ^c   Pilcher, David ^a,d,e   Bellomo, Rinaldo ^a,c  

^a MONASH UNIVERSITY   (Australia)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c AUSTIN HEALTH   (Australia)

^d ANZICS APD   (Australia)

^e ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; AUSTRALIA; COMORBIDITY; CONTROLLED STUDY; CRITICALLY ILL PATIENT; FEMALE; HOSPITAL DISCHARGE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEW ZEALAND; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; SEPSIS; SEPTIC SHOCK;

AGED; AUSTRALIA; CRITICAL ILLNESS; FEMALE; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; NEW ZEALAND; PATIENT DISCHARGE; RETROSPECTIVE STUDIES; SEPSIS; SHOCK, SEPTIC;

EID: 84897556197     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.2637     Document Type: Article

References (45)

1. Gaieski DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med. 2013;41(5):1167-1174.
2. Brun-Buisson C, Meshaka P, Pinton P, Vallet B; EPISEPSIS Study Group. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med. 2004;30(4):580-588. (Pubitemid 38530092)
3. Bernard GR, Vincent JL, Laterre PF, et al; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344(10):699-709.
4. Rivers E, Nguyen B, Havstad S, et al; Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345(19):1368-1377.
5. Annane D, Sébille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288(7):862-871.
6. Warren BL, Eid A, Singer P, et al; KyberSept Trial Study Group. Caring for the critically ill patient: high-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001;286(15):1869-1878. (Pubitemid 33010239)
7. Abraham E, Reinhart K, Opal S, et al; OPTIMIST Trial Study Group. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003;290(2):238-247. (Pubitemid 37430063)
8. Abraham E, Laterre P-F, Garg R, et al; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med. 2005;353(13):1332-1341. (Pubitemid 41362701)
9. Ranieri VM, Thompson BT, Barie PS, et al; PROWESS-SHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366(22):2055-2064.
10. Annane D, Vignon P, Renault A, et al; CATS Study Group. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet. 2007;370(9588):676-684. (Pubitemid 47299251)
11. Brunkhorst FM, Engel C, Bloos F, et al; German Competence Network Sepsis (SepNet). Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2008;358(2):125-139.
12. Russell JA, Walley KR, Singer J, et al; VASST Investigators. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358(9):877-887. (Pubitemid 351397087)
13. Sprung CL, Annane D, Keh D, et al; CORTICUS Study Group. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008;358(2):111-124.
14. Annane D, Cariou A, Maxime V, et al; COIITSS Study Investigators. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA. 2010;303(4):341-348.
15. Opal SM, Laterre P-F, Francois B, et al; ACCESS Study Group. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA. 2013;309(11):1154-1162.
16. Peake SL, Bailey M, Bellomo R, et al; ARISE Investigators, for the Australian and New Zealand Intensive Care Society Clinical Trials Group. Australasian resuscitation of sepsis evaluation (ARISE): a multi-centre, prospective, inception cohort study. Resuscitation. 2009;80(7):811-818.
17. Ho BCH, Bellomo R, McGain F, et al. The incidence and outcome of septic shock patients in the absence of early-goal directed therapy. Crit Care. 2006;10(3):R80.
18. Aberegg SK, Richards DR, O'Brien JM. Delta inflation: a bias in the design of randomized controlled trials in critical care medicine. Crit Care. 2010;14(2):R77.
19. Bellomo R, Lipcsey M. Xigris 2011: deja vu all over again? Crit Care Resusc. 2011;13(4):211-212.
20. Stow PJ, Hart GK, Higlett T, et al; ANZICS Database Management Committee. Development and implementation of a high-quality clinical database: the Australian and New Zealand Intensive Care Society Adult Patient Database. J Crit Care. 2006;21(2):133-141. (Pubitemid 43850185)
21. 3101.0: Australian Demographic Statistics, Dec 2012. Australian Bureau of Statistics. http://www.abs.gov.au/AUSSTATS/absat.nsf/DetailsPage/3101.0Dec 2012?OpenDocument. Accessed August 1, 2013.
22. QuickStats About New Zealand's Population and Dwellings. Statistics New Zealand. http://www.stats.govt.nz/Census/2006CensusHomePage/QuickStats/ quickstats-about-a-subject/nzs-population-and-dwellings.aspx. Accessed August 1, 2013.
23. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818-829. (Pubitemid 15250137)
24. Knaus WA, Wagner DP, Draper EA, et al. The APACHE III prognostic system: risk prediction of hospital mortality for critically ill hospitalized adults. Chest. 1991;100(6):1619-1636.
25. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20(6):864-874.
26. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure: on behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707-710.
27. Finfer S, Bellomo R, Lipman J, French C, Dobb G, Myburgh J. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med. 2004;30(4):589-596. (Pubitemid 38530093)
28. Grønlykke L, Brandstrup SL, Perner A. Data from clinical database on septic shock are valid. Dan Med J. 2012;59(10):A4522.
29. Banta JE, Joshi KP, Beeson L, Nguyen HB. Patient and hospital characteristics associated with inpatient severe sepsis mortality in California, 2005-2010. Crit Care Med. 2012;40(11):2960-2966.
30. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348(16):1546-1554. (Pubitemid 36437931)
31. Zimmerman JE, Kramer AA, Knaus WA. Changes in hospital mortality for United States intensive care unit admissions from 1988 to 2012. Crit Care. 2013;17(2):R81.
32. Levy MM, Dellinger RP, Townsend SR, et al; Surviving Sepsis Campaign. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Crit Care Med. 2010;38(2):367-374.
33. Vincent J-L, Opal SM, Marshall JC, Tracey KJ. Sepsis definitions: time for change. Lancet. 2013;381(9868):774-775.
34. Zhao H, Heard SO, Mullen MT, et al. An evaluation of the diagnostic accuracy of the 1991 American College of Chest Physicians/Society of Critical Care Medicine and the 2001 Society of Critical Care Medicine/European Society of Intensive Care Medicine/American College of Chest Physicians/American Thoracic Society/Surgical Infection Society sepsis definition. Crit Care Med. 2012;40(6):1700-1706.
35. Perner A, Haase N, Guttormsen AB, et al; 6S Trial Group; Scandinavian Critical Care Trials Group. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med. 2012;367(2):124-134.
36. Stevenson EK, Rubenstein AR, Radin GT, Wiener RS, Walkey AJ. Two decades of mortality trends among patients with severe sepsis: a comparative meta-analysis. Crit Care Med. 2014;42(3):625-631.
37. Levy MM, Artigas A, Phillips GS, et al. Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe: a prospective cohort study. Lancet Infect Dis. 2012;12(12):919-924.
38. Kumar G, Kumar N, Taneja A, et al; Milwaukee Initiative in Critical Care Outcomes Research Group of Investigators. Nationwide trends of severe sepsis in the 21st century (2000-2007). Chest. 2011;140(5):1223-1231.
39. Miller RR III, Dong L, Nelson NC, et al; Intermountain Healthcare Intensive Medicine Clinical Program. Multicenter implementation of a severe sepsis and septic shock treatment bundle. Am J Respir Crit Care Med. 2013;188(1):77-82.
40. Martin GS, Mannino DM, Moss M. The effect of age on the development and outcome of adult sepsis. Crit Care Med. 2006;34(1):15-21. (Pubitemid 43032375)
41. Webb SA, Litton E, Barned KL, Crozier TM. Treatment goals: health care improvement through setting and measuring patient-centred outcomes. Crit Care Resusc. 2013;15(2):143-146.
42. Lindenauer PK, Lagu T, Shieh MS, Pekow PS, Rothberg MB. Association of diagnostic coding with trends in hospitalizations and mortality of patients with pneumonia, 2003-2009. JAMA. 2012;307(13):1405-1413.
43. Poukkanen M, Vaara ST, Pettilä V, et al; FINNAKI study group. Acute kidney injury in patients with severe sepsis in Finnish intensive care units. Acta Anaesthesiol Scand. 2013;57(7):863-872.
44. Myburgh JA, Finfer S, Bellomo R, et al; CHEST Investigators; Australian and New Zealand Intensive Care Society Clinical Trials Group. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med. 2012;367(20):1901-1911.
45. Graham PL, Cook DA. Prediction of risk of death using 30-day outcome: a practical end point for quality auditing in intensive care. Chest. 2004;125(4):1458-1466. (Pubitemid 38501363)